Davide Corti, Ph.D.

SENIOR VICE PRESIDENT, ANTIBODY RESEARCH

Davide Corti, Ph.D., has served as Vir’s Senior Vice President of Antibody Research since 2018. Upon completion of his doctoral training, Dr. Corti was appointed Chief Scientific Officer of Humabs BioMed in 2009, which was acquired by Vir in August 2017. Dr. Corti’s career has centered around the discovery, characterization and development of human monoclonal antibodies against a number of major viral and bacterial pathogens. His research, as well as the industry, government and academic collaborations he has led, have resulted in two important medicines: ansuvimab for the treatment of Ebola and sotrovimab for the early treatment of COVID-19. Dr. Corti received a Bachelor’s degree in pharmaceutical biotechnology from the University of Milan in Italy and a Ph.D. in immunology from the University of Bern in Switzerland.